Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sevelamer hydrochloride (Sevelamer HCl) 是一种磷酸盐结合药物,用于通过与膳食磷酸盐结合并阻止其吸收来治疗高磷血症。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
50 mg | ¥ 410 | 现货 | ||
100 mg | ¥ 631 | 现货 | ||
200 mg | ¥ 1,131 | 现货 | ||
500 mg | ¥ 2,189 | 现货 |
产品描述 | Sevelamer hydrochloride (Sevelamer HCl) is a phosphate binding drug used to treat hyperphosphatemia via binding to dietary phosphate and prevents its absorption. |
体内活性 | Sevelamer is as effective as CaCO3 in reducing serum phosphorus, calcium-phosphorus product, and attenuating secondary hyperparathyroidism in nephrectomized rats (U) fed high phosphorus (HP) diet. Sevelamer results in markedly lower calcium deposition in the myocardium and aorta compared to control rats. [1] Sevelamer suppresses calcification of the aorta media, and also the osteoid volume, fibrosis volume, and porosity ratio of femurs in chronic renal failure rats. [2] Sevelamer results in a significantly lower degree of atherosclerosis and vascular calcification in uremic mice when compared with uremic control mice. Sevelamer exerts an effect on both intima and media calcification in uremic mice. [3] Sevelamer treatment controlled serum P independent of increases in serum Ca, thus reducing serum calcium-phosphate product and further deterioration of renal function, as indicated by the highest creatinine clearances in uremic rats. Sevelamer is as effective as CaCO3 in the control of high-P-induced SH, as shown by similar serum PTH levels, parathyroid (PT) gland weight, and markers of PT hyperplasia. Sevelamer causes a dramatic reduction of renal Ca deposition compared with both uremic + high-P diet (U-HP) and the U-HP+CaCO3 diet. [4] Sevelamer hydrochloride results in a fall in urine pH, as well as an increase in urinary ammonium and calcium excretion consistent with an increase in net acid excretion in animal model. [5] |
别名 | Sevelamer HCl |
分子量 | N/A |
分子式 | (C3H7N·C3H5ClO·HCl)x |
CAS No. | 152751-57-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: < 1 mg/mL (insoluble or slightly soluble)
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Sevelamer hydrochloride 152751-57-0 Autophagy Metabolism FXR NR1H4 Sevelamer HCl inhibit Inhibitor Sevelamer Sevelamer Hydrochloride inhibitor